Title
Association of preoperative glucose concentration with myocardial injury and death after non-cardiac surgery (GlucoVISION): a prospective cohort study
Date Issued
01 October 2018
Access level
open access
Resource Type
journal article
Author(s)
Punthakee Z.
Iglesias P.P.
Alonso-Coello P.
Gich I.
India I.
Jover R.D.
Gerstein H.C.
Devereaux P.J.
Publisher(s)
Lancet Publishing Group
Abstract
Background: Myocardial injury after non-cardiac surgery (MINS) is the most common perioperative cardiovascular complication and is independently associated with 30-day mortality. We aimed to assess the association between preoperative glucose concentration and postoperative MINS and mortality. Methods: The VISION study is a prospective cohort study done at 12 centres in eight countries. Patients aged 45 years or older who required at least one overnight hospital admission for non-cardiac surgery were enrolled from Aug 6, 2007, to Jan 11, 2011. In the GlucoVISION analysis, we assessed the relations between preoperative casual or fasting glucose concentration and MINS within 3 days after surgery using logistic regression, and 30-day mortality using Cox proportional regression, in people with and without diabetes. Findings: 11 954 patients were included in this analysis, of whom 2809 (23%) had diabetes. Within the first three postoperative days, MINS occurred in 813 (7%) patients. 249 (2%) patients died by day 30. More patients with diabetes had MINS (odds ratio [OR] 1·98 [95% CI 1·70–2·30]; p<0·0001), and died (OR 1·41 [1·08–1·86]; p=0·016) than did patients without diabetes. Casual glucose concentrations were associated with MINS in all patients (adjusted OR 1·06 [1·04–1·09] per 1 mmol/L increment in glucose; p=0·0003), and with death in patients without diabetes (adjusted hazard ratio [HR] 1·13 [95% CI 1·05–1·23] per mmol/L; p=0·002). We noted a progressive relation between unadjusted fasting glucose concentration and both MINS (OR 1·14 [1·08–1·20] per mmol/L; p<0·0001), driven by the effect in the subgroup without previous diabetes (p interaction =0·025), and 30-day mortality (HR 1·10 [1·02–1·19] per mmol/L; p=0·013). For patients without diabetes, casual glucose of more than 6·86 mmol/L and fasting glucose of more than 6·41 mmol/L predicted MINS (OR 1·71 [1·36–2·15]; p<0·0001, and OR 2·71 [1·85–3·98]; p<0·0001, respectively). For patients with diabetes, only casual glucose concentration more than 7·92 mmol/L predicted MINS (OR 1·47 [1·10–1·96]; p=0·0096). Interpretation: Preoperative glucose concentration, particularly casual glucose concentration, predicts risk for postoperative cardiovascular outcomes, especially in patients without diabetes. Funding: Full funding sources listed at the end of the paper (see Acknowledgments).
Start page
790
End page
797
Volume
6
Issue
10
Language
English
OCDE Knowledge area
Sistema cardiaco, Sistema cardiovascular
Scopus EID
2-s2.0-85055043030
PubMed ID
Source
The Lancet Diabetes and Endocrinology
ISSN of the container
22138587
Sponsor(s)
ZP reports receipt of grants from Amgen, AstraZeneca/Bristol-Myers Squibb, Lexicon, Merck, Novo Nordisk, and Sanofi; and personal fees for speaking and advising from Abbott, AstraZeneca/Bristol-Myers Squibb, Boehringer Ingelheim/Eli Lilly, Janssen, Merck, Novo Nordisk, Pfizer, and Sanofi. HCG reports research grant support from Sanofi, Lilly, AstraZeneca, Boehringer Ingelheim, Merck, Abbott, and Novo Nordisk; honoraria for speaking from Sanofi, Novo Nordisk, Merck, Boehringer Ingelheim, and AstraZeneca; and consulting fees from Sanofi, Lilly, AstraZeneca, Merck, Novo Nordisk, Abbott, Janssen, and Boehringer Ingelheim. PJD reports receipt of grants from Abbott Diagnostics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Covidien, Octapharma, Philips Healthcare, Roche Diagnostics, and Stryker; and honoraria for advising from AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline. All other authors declare no competing interests.
ZP had full access to the data in the study and takes responsibility for the integrity of the work. We thank Diane Heels-Ansdell for statistical advice. Funding for VISION and its substudies was provided by the following institutions from Canada: Canadian Institutes of Health Research (six grants, including one specifically for GlucoVISION; Ottawa, ON); Heart and Stroke Foundation of Ontario (two grants; Toronto, ON); Academic Health Science Centres Alternative Funding Plan Innovation Fund Grant (Toronto, ON); Population Health Research Institute Grant (Hamilton, ON); CLARITY Research Group Grant; McMaster University, Department of Surgery, Surgical Associates Research Grant (Hamilton, ON); Hamilton Health Science New Investigator Fund Grant (Hamilton, ON); Hamilton Health Sciences Grant (Hamilton, ON); Ontario Ministry of Resource and Innovation Grant (Toronto, ON); Stryker Canada (Waterdown, ON); McMaster University, Department of Anesthesiology (two grants; Hamilton, ON); Saint Joseph's Healthcare, Department of Medicine (two grants; Hamilton, ON); Father Sean O'Sullivan Research Centre (two grants; Hamilton, ON); McMaster University, Department of Medicine (two grants; Hamilton, ON); Hamilton Health Sciences Summer Studentships (six grants; Hamilton, ON); McMaster University, Department of Clinical Epidemiology and Biostatistics Grant (Hamilton, ON); McMaster University, Division of Cardiology Grant (Hamilton, ON); Canadian Network and Centre for Trials Internationally Grant (Hamilton, ON); Winnipeg Health Sciences Foundation Operating Grant (Winnipeg, MB); University of Manitoba, Department of Surgery Research Grant (two grants; Winnipeg, MB); Diagnostic Services of Manitoba Research Grant (two grants; Winnipeg, MB); Manitoba Medical Services Foundation Grant (Winnipeg, MB); Manitoba Health Research Council Grant (Winnipeg, MB); University of Manitoba, Faculty of Dentistry Operational Fund (Winnipeg, MB); University of Manitoba, Department of Anesthesia Grant (Winnipeg, MB); and University Medical Group, Department of Surgery, University of Manitoba, start-up fund (Winnipeg, MB). Funding from Australia: National Health and Medical Research Council Program Grant (Canberra, ACT); and Australian and New Zealand College of Anesthesiologists Grant (Sydney, NSW). Funding from Brazil: Projeto Hospitais de Excelência a Serviço do SUS (PROADI-SUS) grant from the Brazilian Ministry of Health in Partnership with Hcor (Cardiac Hospital Sao Paulo-SP; Sao Paulo). Funding from China: Public Policy Research Fund, Research Grant Council, Hong Kong SAR (Hong Kong); and General Research Fund, Research Grant Council, Hong Kong SAR (Hong Kong). Funding from Colombia: School of Nursing, Universidad Industrial de Santander (Bucaramanga); Grupo de Cardiología Preventiva, Universidad Autónoma de Bucaramanga (Bucaramanga); Fundación Cardioinfantil–Instituto de Cardiología (Bogota); and Alianza Diagnóstica SA (Bucaramanga). Funding from India: St John's Medical College and Research Institute Grant, Division of Clinical Research and Training Grant (Bangalore). Funding from Malaysia: University of Malaya Research Grant (Kuala Lumpur); and University of Malaya, Penyelidikan Jangka Pendek Grant (Kuala Lumpur). Funding from Spain: Instituto de Salud Carlos III (Madrid); and Fundació La Marató de TV3 (Esplugues de Llobregat). Funding from Switzerland: Roche Diagnostics Global Office (two grants; Basel, Switzerland). Funding from USA: American Heart Association Grant (Dallas, TX), National Institute for General Medical Sciences (K23 GM087534), National Institutes of Health (Bethesda, MD), and a grant to Washington University Institute of Clinical and Translational Sciences (UL1RR024992). Funding from UK: National Institute for Health Research (London).
Sources of information:
Directorio de Producción Científica
Scopus